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Abstract— The origin of many neurodegenerative disorders 
like Alzheimer’s Disease (AD) lies in protein processing failures, 
which leads to protein aggregation and accumulation as amyloid 
fibrils. Abnormal accumulation and aggregation of beta amyloid 
peptide (Aβ) eventually lead to the formation and cerebral 
deposition of amyloid plaques, the major pathological hallmark 
in AD. Aβ1-40 and Aβ1-42 are the predominant components of 
senile plaques formed in AD brain. The aggregation of Aβ is 
associated with neurodegeneration, loss of cognitive ability, and 
premature death. Understanding the aggregation mechanism and 
how to inhibit aggregate formation is therefore crucial. In light of 
the proposed link between oxidative stress, unregulated immune 
response and neurodegeneration, it is suggested that use of 
antioxidants may be beneficial for inhibiting Aβ fibrillogenesis. 
Therefore, endogenous and dietary antioxidants may offer a 
protective or even therapeutic alternative against amyloidosis. In 
this study, several compounds isolated from natural products are 
screened for the in vitro antiamyloidogenic activity. Novel 
electrospray ionization (ESI) mass spectrometry (MS)-based 
methodologies are employed to assess the noncovalent 
interactions between the Aβ and isolated components from 
natural products. The specificity and the stability of these 
noncovalent complexes were examined under different 
experimental conditions, whereas their relative binding strength 
was assessed. In addition, MS proteolytic mapping was employed 
to provide information on the noncovalent binding site of the 
bioactive molecule on the Aβ residues. This may shed some light 
into the mechanisms of AD pathology and provide insights into 
novel agents that can be employed towards prevention or even 
treatment of AD.  
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I. INTRODUCTION 
Dementia, including Alzheimer’s disease (AD), is 
associated with a decline in memory, loss of cognitive ability 
and premature death, and represents one of the biggest global 
public health challenges. AD is the most common 
neurodegenerative disease worldwide accounting for 60% to 
80% of senile dementia cases and it has a major impact on 
health along with financial ramifications in Western world. 
The prevalence of AD doubles every 5 years after the age of 
60 years, increasing from a prevalence of 1% among those 60–
64 years old up to 40% of those aged 85 years and older [1]. 
Even though the greatest risk factor for AD is advancing age, 
individuals younger than age 65 can also develop the disease. 
AD is the fourth main cause of death affecting more than 35 
million people worldwide whereas it is projected to double in 
2030, and almost quadruple until 2050 [2], whereas the 
number of caregivers will rise up to 216 million. Furthermore, 
the direct and indirect economic cost associated with the 
disease in 2010 was estimated at more than $600 billion 
worldwide, corresponding to more than 1% of the aggregated 
worldwide Gross Domestic product (GDP), thus making AD 
and other dementias the world’s “18th largest economy” [3]. It 
should be mentioned that the average lifespan of sufferers is 
between 7-10 years from the time of diagnosis and no cure is 
presently known. In addition, most of the people suffering 
from AD need personal care with their needs starting early in 
the disease course and growing constantly over time, thus 
contributing to the high cost associated with the disease. 
Therefore, finding ways to prevent and reverse this trend is 
critical and represents a priority area of the European Union 
and most countries in the world.  
At pathological level, AD is a progressive neurodegenerative 
disorder characterized by selective, but widespread, neuronal 
atrophy and degeneration, and synaptic loss in various brain 
regions such as hippocampus and cortex that eventually result 
in diffuse cerebral atrophy. The cause of AD remains 
ambiguous, even though many hypotheses have been proposed 
to enlighten its mechanism. Research over the last twenty 
years has revealed and clarified the pathological pathways and 
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 mechanisms of the disease. The prevailing hypotheses are 
centered on the amyloid beta peptide (Aβ) deposits and 
neurofibrillary tangles (NFTs) which have been described in 
patients with AD [4]. Even though the causes and effects 
associating protein aggregation and nervous system 
degeneration are mostly unknown, the disease-specific 
aggregated proteins and peptides have apparent diagnostic and 
even therapeutic implications [5]. The central role of the 
amyloid plaques and the amyloid cascade hypothesis [6] in 
AD pathogenesis has been confirmed by discovering AD-
related polymorphisms in genes encoding the Amyloid 
Precursor Protein (APP) and the enzymes converting APP into 
amyloidogenic compounds [7]. Human AD neuritic plaques 
consist primarily of aggregates of Aβ peptide, which is a 
cleavage product of APP and it is invariably deposited in the 
brains of AD patients. In particular, Aβ1-40 and Aβ1-42 are the 
predominant components in amyloid plaques and they are a 
pathological hallmark of AD. In the process of amyloidosis, 
the Aβ peptide misfolds and aggregates to form an initial 
nucleus, comprising of a small number of Aβ molecules, 
followed by a rapid elongation stage after which incorporates 
new Aβ molecules. The main mechanisms proposed to justify 
Αβ’s neurotoxicity are oxidative stress and unregulated 
inflammatory / immune response, and they are believed to 
play a key role for the processes inherent to AD [8, 9]. The 
suggested link between oxidative stress, inflammatory 
response and AD, justifies the use of anti-inflammatory agents 
as therapeutic approaches against AD [10]. On the other hand, 
in view of the amyloid cascade hypothesis there have been 
several efforts to develop therapies for AD by reducing the Aβ 
levels in the brain [11,12], including inhibition of amyloid 
formation by controlling APP proteolytic cleavage (secretase 
inhibitors) [13,14]. Other therapeutic alternatives include 
control of Aβ degradation [15], immunization with Aβ 
[16,17], inhibition of Aβ aggregation, and/or stimulation of its 
disaggregation by molecules that potentially bind on the 
peptide and stabilize its structure, thus becoming potential 
inhibitors of amyloidosis [18,19]. To date, the only FDA 
approved drugs for disease treatment is a group of 
acetylcholinesterase inhibitors: donepezil (Aricept), 
rivastigmine (Exelon), galantamine (Reminyl) while 
memantine (Ebixa) is also used in clinical practice. However, 
these drugs are used as symptomatic treatment and they are 
unable to stop or reverse the progression of the disease, not 
offering a definitive cure. Despite the enormous scientific 
progress and research effort on disease characterization and 
therapeutic treatment, there is still no cure for AD. That has 
emphasized the need for elucidating the AD underlying 
mechanisms, the availability of a drug treatment as well as the 
importance for diagnostic markers for AD [20] as the early 
symptoms of AD are rather subtle.  
Plants containing antioxidants and phytoestrogens such as α-
tocopherol have been employed in the management of AD 
[21]. It has been proposed that the plant-derived and dietary 
antioxidants may offer an ideal therapeutic regime for 
protection against the risk of the aforementioned disease. As a 
matter-of-fact recently standardized phytopreparation of 
Gingko biloba has been approved in some European countries 
for the treatment of AD [22]. Therefore, plants and their 
bioactive natural products are of great interest for the search of 
new molecules acting against AD. In particular, plants from 
the Mediterranean basin (a global biodiversity “hot-spot” [23], 
in which only the Southern part of Greece offers 6,000 plants 
species and 1,200 endemic [24]) are worth to be investigated. 
In this study, several natural compounds isolated from plants 
endemic in Greece, are evaluated in terms of their anti-
neurodegenerative properties.  
Mass Spectrometry (MS) is a powerful analytical tool for 
providing information on the primary structure of 
biomolecules, using small amounts of sample [25]. MS has 
played an important role in the design, discovery and 
development of new pharmaceuticals, from the earliest stages 
of disease determination through the final stages of clinical 
testing. The advent of electrospray ionization (ESI) and 
matrix-assisted laser desorption/ ionization (MALDI) methods 
combined with the rapid proliferation of several types of mass 
analyzers has revolutionized the applicability of MS for 
studying proteins of high molecular weights by themselves or 
when they are bound to ligands. That, in turn, has opened the 
way to elucidate macromolecular structures and study their 
noncovalent interactions with small molecules or other 
macromolecules [26], which are important aspects in 
understanding their biological function and developing new 
therapeutics. It is well known that weak noncovalent 
interactions can often trigger cellular functions such as those 
between enzyme and substrate, protein and ligand, protein and 
protein, antibody and antigen. Interruption of these non-
covalent interactions can cause abnormalities, which often 
lead to diseases. Hence the elucidation of the structure and the 
formation mechanism of these noncovalent complexes can 
lead to a better understanding of the disease process and 
provide insight towards the design and development of a 
therapeutic approach [27,28].  
More specifically, ESI is a mild ionization method, which 
allows the preservation of protein conformations and protein–
ligand noncovalent interactions/associations in the gas phase 
[29,30]. That renders ESI MS a suitable technique for the 
detection of macromolecular interactions in real time [26], the 
definition of the stoichiometry and the topology of the 
interacting species, as well as the quantification of their 
corresponding affinities [31,32]. These noncovalent 
interactions between peptides/proteins and ligands may be 
involved in triggering cellular functions and causing diseases. 
This is illustrated in our efforts to screen and identify potential 
inhibitors for the Aβ peptide aggregation. In the present study, 
the noncovalent interaction between Aβ and several natural 
products was monitored by ESI MS. The detection of the 
noncovalent interactions between the Aβ peptide and the 
natural product/ligand may shed some light into the 
mechanisms of AD pathology and provide insights into the 
active compounds that can be employed as novel agents 
towards prevention or even treatment of AD. 
II. MATERIALS AND METHODS 
A. Sample Preparation for in vitro Screening  
An aliquot of a freshly prepared Aβ (1-40) solution 100 µΜ 
(monoisotopic Mr 4327.15, average Mr 4329.9; Bachem AG, 
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 Bubendorf, Switzerland) in deionized water was added into 
150 µL of an equimolar ligand solution (100 µΜ) in 2 mM 
ammonium acetate (Merck, Darmstad, Germany) – 0.5 % 
acetic acid (Pancreac, Barcelona, Spain). All solvents used 
were of analytical grade purity. Mass spectral analysis was 
carried out on a Waters Premier quadrupole reflectron time-of-
flight (QqTOF) and a Sciex API-III triple quadrupole 
instruments equipped with a standard atmospheric pressure 
ionization source in the positive ion mode. Oleuropein (OE) 
(Mr monoisotopic: 540.18) was isolated from olive leaves of 
Olea europaea (var. koroneiki), according to a previously 
described procedure [33] with greater than 99% purity, as it 
was assessed by NMR analysis. Major biologically active 
components of Crocus sativus L. were extracted, separated 
and isolated from dried stigmas of saffron flowers by semi-
preparative HPLC as previously described [34]. Accurate 
mass measurements of the crocus-derived bioactive 
components were taken on the QqTOF Premier high-
resolution MS employing micro-spray ESI. Other natural 
products (NP) and endogenous compounds, such as quercetin, 
quercetin glycoside, kaempferol and melatonin (M) were 
purchased and used without any prior purification.  
B. Enzymatic Digestion and Mapping Analysis 
Determination of the noncovalent binding site of the 
bioactive molecule on the Aβ peptide was carried out by 
tryptic and Glu-C mapping. The two different proteolytic 
digestion protocols were similar to the ones described in the 
mapping of the Aβ – M noncovalent complex [35]. The 
resulting peptide digests were analyzed by ESI FT-ICR MS on 
a Bruker Daltonics BioAPEX-94e superconducting 9.4 T FT-
ICR mass spectrometer. It should be noted that the enzyme-
derived peptide mixtures were desalted on a ZipTipC18 pipette 
tip (Millipore, Bedford, MA, USA) prior to MS analysis using 
the protocol that was previously described [35].   
C. Binding Strength Studies  
In the analysis of the noncovalent complex between Aβ and 
the bioactive molecule, the mass spectrometer was tuned with 
gentle desolvation parameters in order to preserve noncovalent 
complexes intact during their transfer from solution to the gas 
phase. In the binding strength studies of the Aβ – M and Aβ – 
OE noncovalent complexes, the +5 charged ion of the 
noncovalent complex was selected and subjected to collision-
induced dissociation (CID) in the collision cell of the API-III 
triple quadrupole mass spectrometer, with collision energies 
ranging from 5 to 20 eV.  
III. RESULTS AND DISCUSSION  
ESI MS is a mild ionization process, which allows the 
preservation of the fragile noncovalent interactions upon their 
transfer from aqueous solutions to the gas phase. Therefore, 
ESI MS represents an ideal method to provide information on 
the Mr of the noncovalent complexes formed in solution, as 
well as the stoichiometry of the interacting species. 
Nevertheless, it should be noted that careful optimization of 
the experimental parameters should be performed especially in 
terms of the entrance potential in the MS ion source, the 
ligand concentration, the pH and the presence of organic 
modifiers in the solution which affect conformational changes 
of the Aβ peptide [35]. For example, elevated values of the ion 
source entrance potential increases the internal energy of the 
complex, which in turn can induce dissociation of the gas 
phase noncovalent complex. The effect of the ion source 
entrance potential on the abundance of the noncovalent 
complex depends on the binding strength of the complex. 
Similarly, careful selection of the solution pH and the amount 
of the organic modifier should be made in order to avoid 
denaturation of the noncovalent interactions. Usually pH 
values lower than 4.0 and addition of an organic modifier such 
as methanol can lead to substantial unfolding of the peptide 
and eventual disruption of noncovalent interactions [35].  
Screening of endogenous antioxidants, such as M or plant-
derived bioactive compounds for binding to Aβ was 
performed by ESI MS. It has been found that only few of the 
compounds studied interact with Aβ via noncovalent 
interactions. It has been shown that Aβ interacts with M and  
 
Figure 1. ESI mass spectra of an equimolar solution of the Aβ 
peptide with Melatonin - M (A), Oleuropein - OE (B) and quercetin 
glycoside (C).  
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 forms noncovalent complexes with a stoichiometry varying 
from 1:1 to 1:2 depending on the incubation time (Figure 1A) 
[35]. Similar observations have been made for other plant-
derived phytochemicals, such as oleuropein (OE) [36] and 
several metabolites thereof such as hydroxytyrosol and 
oleocanthal. ESI MS analysis of the Aβ – OE sample solution 
generated a mass spectrum containing the multiply charged 
ion envelope corresponding to the +4 (m/z 1083.5), +5 (m/z 
867.0) and +6 (m/z 722.5) charge states of Aβ and a “bell-
shaped” distribution of multiply charged ions at m/z 1218.5, 
975.0, and 812.0 (Figure 1B), which corresponded to the +4, 
+5, and +6 charge states of the 1:1 Aβ:OE noncovalent 
complex, respectively. 
Deconvolution of the observed ion envelopes gave rise to 
Mr of 4330 and 4870.0, with the latter being in good 
agreement with the theoretical average mass of 4870.4 for the 
1:1 Aβ:OE noncovalent complex. Thus, the electrospray 
ionization process and the experimental conditions maintained 
the existing interactions in solution, thereby showing that OE 
forms noncovalent complexes with Aβ with 1:1 stoichiometry. 
The increased sensitivity of the QqTOF and the FT-ICR 
systems allowed the detection of low-abundance moieties such 
as the Met35(O)-containing Aβ1-40 variant and the OE 1:1 
noncovalent interaction thereof [37]. This is an important 
observation because it shows that the antioxidant OE can bind 
not only to Aβ but also to the already oxidized species 
AβMet35(O), thus showing potential use towards preventing 
its subsequent aggregation. Similar noncovalent interactions 
between the Aβ peptide and glycosylated crocetin 
apocarotenoids (crocins) isolated from Crocus sativus L. have 
been recently observed [38].  
It is well documented that random protein–ligand 
interactions may occur at higher concentrations. Therefore, the 
specificity of the Aβ – ligand noncovalent interaction was 
evaluated at low concentration levels of the interacting species 
(5-100 µΜ). The occurrence of nonspecific aggregation in the 
gas phase can be avoided by reducing the concentration of the 
interacting species. In our case, the ESI signals corresponding 
to the 1:1 Aβ – OE and Aβ – M noncovalent complexes were 
present for all concentration levels, thus indicating a very 
specific interaction. On the contrary, ESI MS analysis of the 
Aβ – quercetin glycoside solution yielded no signals 
corresponding to the formation of a noncovalent complex 
(Figure 1C); thus showing the specificity of the previously 
observed interactions of the Aβ peptide with OE and M. 
The stability of the noncovalent complexes was studied 
under several experimental parameters, such as elevated ion 
source entrance potential, low pH values and the presence of 
organic modifier. The overall tested conditions of the ESI 
process do not perturb the interactions that govern the 
complex formation of Aβ with M and especially with OE, with 
the latter showing considerable stability even under 
experimental conditions, which usually do not favor 
noncovalent interactions (e.g., high organic modifier content). 
It should be noted that addition of 45% MeOH yielded the 
most abundant signals associated with the complex, whereas 
the Aβ – OE noncovalent complex was preserved even at 
higher MeOH content although the observed ESI signals had 
lower S/N. The preservation of the Aβ – OE noncovalent 
complex at these conditions reflects the high binding strength 
of this interaction.  
The binding strength of the Aβ – ligand complex was first 
examined under collisional excitation in the declustering 
region of the mass spectrometer. Thus, the effect of the ion 
source entrance potential on the abundance of the noncovalent 
complex was studied at entrance potential values ranging from 
35 to 100 V. That yielded a qualitative assessment of the 
binding energy of the Aβ – ligand noncovalent complexes, 
with the ones corresponding to OE and some crocins 
presenting the highest binding affinities. Moreover, binding 
strength studies of the Aβ – M and Aβ – OE noncovalent 
complexes were performed by ESI tandem MS analysis 
(Figure 2). In this study the +5 charged ion of the noncovalent 
complex was selected and subjected to CID in the collision 
cell of a triple quadrupole mass spectrometer at collision 
energies ranging from 5 to 20 eV. It is clearly shown that it 
takes more energy to dissociate the Aβ – OE signal than that 
of the Aβ – M, thus demonstrating the higher binding strength 
of the Aβ – OE noncovalent complex over that of the Aβ – M 
counterpart.  
 
Figure 2. Binding strength studies of the Aβ – M and Aβ – OE 
noncovalent complexes as demonstrated by the MS/MS dissociation 
curves of the +5 charged ion of the associated noncovalent complex.  
 
Concerning the binding site of the ligands on Aβ, two 
different proteolytic digestion protocols with trypsin and Glu-
C protease have been employed combined with ESI FT-ICR 
MS analysis of the resulting proteolytic fragments. In case of 
the M and OE ligands, the resulting mass spectral data indicate 
that the [4-11] Aβ amino acid sequence and the [17-28] 
hydrophobic region of Aβ are responsible for the noncovalent 
interaction [37]. This mapping study revealed that the 
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 interacting region of Aβ with M and OE lies within the 
hydrophobic region of the peptide, which is also responsible 
for the β-sheet conformation in aqueous solutions and 
consequently its aggregation. It has also been reported that the 
[17-21] hydrophobic area may play a controlling role in 
fibrillogenesis [39]. This proteolytic MS mapping information 
on the binding site could be used to reveal the specific 
residues that are involved in Aβ’s interaction and fibrillation 
process.  
Following the initial ESI MS screening of the inhibitory 
ability of the bioactive compounds against Aβ aggregation, in 
vitro scanning of the compounds of interest towards the 
inhibition of APP misprocessing and Aβ generation, as well as 
the abnormal tau hyperphosphorylation, will be performed on 
different human and mouse neuronal cell lines. These assays 
will provide input for the selective and targeted selection of 
the most active molecules in terms of anti-amyloidogenic 
activity.  
IV. CONCLUSION 
This study demonstrates the excellent suitability of ESI MS 
for studying noncovalent interactions between Aβ and 
biologically active components isolated from NPs. The 
presented ESI MS-based methodology may serve as a 
screening tool for evaluating NPs and structural analogues 
thereof, thus facilitating the design of novel potential anti-
amyloidogenic agents. Moreover, the in vitro screening using 
MS-based approaches is an excellent preliminary step for the 
subsequent evaluation stage by cell viability assays involving 
different human and mouse neuronal cell lines. The successful 
detection of these noncovalent complexes of Aβ with NPs 
could be invaluable in the area of neuroscience research. This 
methodology could allow real-time monitoring of the 
aforementioned interactions, thus shedding some light into the 
mechanisms of AD pathology and facilitating the design and 
development of novel compounds, which could act as 
protective or even therapeutic agents against AD. These NPs 
and derivatives thereof can be eventually exploited, in the 
form of nutraceuticals and/or drug formulations towards the 
prevention and/or treatment of AD.  
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